Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
491.40    -13.10 (-2.60%)
Bid:
498.00
Ask:
500.00
Spread: 2.00 (0.402%)
Market Cap: £2.17b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Judgment re litigation

29 Sep 2015 14:58

29 September 2015 – Tate & Lyle PLC

Judgment handed down in litigation regarding sale of EU Sugars business in 2010

Tate & Lyle PLC (Tate & Lyle) announces that Judgment was handed down today at the Commercial Court in London in the case brought by American Sugar Refining, Inc. (“ASR”) in which it made a number of claims totalling around £40 million in relation to its acquisition of Tate & Lyle’s EU Sugars business in September 2010 for a consideration of £211 million. The Court found in favour of ASR on two elements of its claims, whilst rejecting all other aspects. Accordingly, in the Judgment, the Court has awarded damages of £18 million (€24.9 million) to ASR (with interest and costs to be determined in due course).

This claim has been disclosed in Tate & Lyle’s Annual Report since 2012 and the expected announcement of this Judgement was highlighted in the Trading Statement on 29 July 2015.

The impact of the Judgment will be reported as an exceptional item within discontinued operations.

END

For more information contact Tate & Lyle PLC:Christopher Marsh, VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media RelationsTel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2015, Tate & Lyle sales totalled £2.7 billion. For more information, please visit http://www.tateandlyle.com. SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150929006222/en/

Copyright Business Wire 2015

Date   Source Headline
4th Jan 20213:04 pmRNSTotal Voting Rights
30th Dec 20201:00 pmRNSBoard Changes
7th Dec 202011:06 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTATE & LYLE ACQUIRES SWEET GREEN FIELDS
5th Nov 20207:00 amRNSHalf-year Report
28th Oct 20207:00 amRNSTate & Lyle to acquire tapioca business
14th Oct 202011:00 amRNSDirector Declaration
7th Oct 20207:00 amRNSDirectorate Change
2nd Oct 202011:55 amRNSDirector/PDMR Shareholding
1st Oct 20202:30 pmRNSTotal Voting Rights
17th Sep 20207:30 amRNSBlock Listing
8th Sep 202010:00 amRNSDirector/PDMR Shareholding
1st Sep 202012:00 pmRNSTotal Voting Rights
5th Aug 20204:30 pmRNSDirector/PDMR Shareholding
3rd Aug 20202:00 pmRNSTotal Voting Rights
23rd Jul 20201:00 pmRNSResult of AGM
23rd Jul 20207:00 amRNSTrading Statement
2nd Jul 20205:45 pmRNSBlock listing Interim Review
1st Jul 20203:06 pmRNSRights attaching to the listed share capital
1st Jul 20203:05 pmRNSTotal Voting Rights
9th Jun 20203:00 pmRNSAnnual Financial Report
2nd Jun 20203:56 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSFinal Results
4th May 20207:00 amRNSTrading Update
1st May 20203:27 pmRNSTotal Voting Rights
3rd Apr 202011:00 amRNSDirector Declaration
1st Apr 202012:26 pmRNSTotal Voting Rights
6th Feb 20207:00 amRNSTrading Statement
30th Jan 202011:45 amRNSDirector/PDMR Shareholding
7th Jan 20202:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202012:41 pmRNSBlock listing Interim Review
19th Dec 20192:00 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSHalf-year Report
3rd Oct 20193:06 pmRNSHolding(s) in Company
1st Oct 201910:14 amRNSTotal Voting Rights
19th Sep 20197:00 amRNSFULL PENSION SCHEME BUY-IN WITH LEGAL & GENERAL
6th Sep 201910:15 amRNSDirector/PDMR Shareholding
30th Aug 201912:00 pmRNSDirector Declaration
21st Aug 201910:00 amRNSDirector/PDMR Shareholding
5th Aug 20193:00 pmRNSIssue of Debt
1st Aug 20192:00 pmRNSTotal Voting Rights
25th Jul 201912:58 pmRNSResult of AGM
18th Jul 20193:00 pmRNSDirector/PDMR Shareholding
17th Jul 20197:02 amRNSChange to Executive Committee
1st Jul 201912:40 pmRNSBlock listing Interim Review
1st Jul 201912:38 pmRNSTotal Voting Rights
1st Jul 201912:00 pmRNSDirector/PDMR Shareholding
10th Jun 201911:30 amRNSAnnual Financial Report
5th Jun 20199:52 amRNSHolding(s) in Company
5th Jun 20199:34 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.